Cardiometabolic Drugs Market revenue to exceed USD 72 Billion by 2035, says Research Nester
21. August 2023 06:00 ET
|
Research Nester
New York, Aug. 21, 2023 (GLOBE NEWSWIRE) -- The global Cardiometabolic Drugs Market size is projected to expand at ~ 6% CAGR between 2023 and 2035. The market is expected to garner a revenue of USD...
Madrigal Pharmaceuticals Reports 2021 Second Quarter Financial Results and Provides Corporate Update
05. August 2021 06:50 ET
|
Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) reports today its second quarter 2021 financial results and provides a summary of corporate...
Global Dyslipidemia Disease Analysis 2020-2027 - Market is Poised to Resume Steady Growth Due to the Introduction of Novel Agents
23. März 2021 08:03 ET
|
Research and Markets
Dublin, March 23, 2021 (GLOBE NEWSWIRE) -- The "Disease Analysis: Dyslipidemia" report has been added to ResearchAndMarkets.com's offering. The report estimates that in 2018, there were...
Madrigal Pharmaceuticals Reports 2020 Fourth Quarter and Full Year Financial Results and Highlights
25. Februar 2021 06:50 ET
|
Madrigal Pharmaceuticals, Inc.
WEST CONSHOHOCKEN, Pa., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today its fourth quarter and full year 2020 financial results and highlights. “We...
Madrigal Pharmaceuticals Highlights Presentations at The Liver Meeting Digital Experience™, The American Association for the Study of Liver Diseases Meeting November 13, 2020, Including NASH Expert Insights on the Ongoing Open Label Arm of Resmetirom 52-Week Phase 3 MAESTRO-NAFLD-1 Trial
13. November 2020 06:50 ET
|
Madrigal Pharmaceuticals, Inc.
Dr. Stephen Harrison will present Resmetirom for the Treatment of NASH: Early Data from the Phase 3 MAESTRO Clinical Trials | The Liver Meeting Digital Experience™, AASLD Product Theater on Friday,...
Madrigal Pharmaceuticals Announces Completion of Enrollment in Phase 3 MAESTRO NAFLD-1 Trial and Reports 2020 Third Quarter Financial Results and Highlights
05. November 2020 06:50 ET
|
Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today that it completed enrollment in its MAESTRO NAFLD-1 clinical trial of resmetirom in...
Madrigal Pharmaceuticals to Present Secondary Analyses of Data from Phase 2 NASH Study of Resmetirom and Symposium at the Digital International Liver Congress™ 2020
26. August 2020 06:50 ET
|
Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., Aug. 26, 2020 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today that on Friday, August 28, 2020 at the Digital International Liver Congress™ 2020,...
CMHC Concludes CMHC West Live Online: Complexities in Cardiometabolic Care.
11. August 2020 12:00 ET
|
Cardiometabolic Health Congress
Boca Raton, FL, Aug. 11, 2020 (GLOBE NEWSWIRE) -- CMHC Concludes CMHC West Live Online: Complexities in Cardiometabolic Care. CMHC West Live Online: Complexities in Cardiometabolic Care concluded...
Madrigal Pharmaceuticals Reports 2020 Second Quarter Financial Results and Highlights
06. August 2020 06:50 ET
|
Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced its second quarter 2020 financial results and highlights: “The Madrigal team and...
National Lipid Association Releases Official Scientific Statement on Genetic Testing in Dyslipidemia
10. Juli 2020 12:30 ET
|
National Lipid Association
JACKSONVILLE, Fla., July 10, 2020 (GLOBE NEWSWIRE) -- The National Lipid Association (NLA) today announced the release of its official scientific statement on the use of genetic testing in the...